HYDERABAD, India – India’s drug authority has granted approval to Mylan Inc.’s Indian arm to market its anti-tuberculosis drug delamanid developed specifically for treating multidrug-resistant tuberculosis (MDR TB). Meanwhile, the country is also actively exploring new entities to tackle the TB problem via public-private partnership.